#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Immunodeficiency congenital Acute on chronic liver failure Peripheral primitive neuroectodermal tumour of soft tissue Dermatomyositis Crigler-Najjar syndrome Retinopathy of prematurity Endocrine ophthalmopathy Congenital cystic kidney disease Erythema multiforme IgA nephropathy Lymphoma Severe myoclonic epilepsy of infancy Marginal zone lymphoma refractory Hereditary motor and sensory neuropathy Acute leukaemia More trials…

    Learn about Rare Diseases

    MELAS syndrome – Treatment Activated PI3 kinase delta syndrome – Life with Disease Leiomyosarcoma metastatic – Diagnostics Mucopolysaccharidosis I – Diagnostics Indolent systemic mastocytosis – Life with Disease Prader-Willi syndrome – Life with Disease Gaucher’s disease type III Nephrotic syndrome Idiopathic inflammatory myopathy – Treatment Langerhans’ cell histiocytosis – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Arsenic Trioxide L-Tryptophan Aavanc80-5'Hotof Zagociguat IADADEMSTAT Cefoxitin Sodium Namodenoson Tominersen Roxithromycin Biotin Riboflavin Bp Fezolinetant Rizolipase R3R01 Isoniazid Oxazepam Abc-24F-116 Exagamglogene Autotemcel Methoxsalen SAROGLITAZAR HEMIMAGNESIUM More therapies…

    Learn about Your Condition

    Neoplasm Malignant peritoneal neoplasm Arterial disorder Hyperparathyroidism secondary Colorectal cancer metastatic Oral neoplasm Testis cancer Adenovirus infection Colorectal adenocarcinoma Primary biliary cholangitis Primary hyperthyroidism Thrombectomy Post procedural infection Gout Normal pressure hydrocephalus More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Digestive System Diseases

  • Title: Study of vedolizumab dose adjustment guided by drug level monitoring in patients with inflammatory bowel disease in remission

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Inflammatory bowel disease
    Investigated Drugs:
    • Vedolizumab
    The Netherlands

  • Study on the Safety of Edoxaban for Patients with Porto-Sinusoidal Vascular Disorder

    Recruiting

    2 1 1
    Investigated Diseases:
    • Porto-sinusoidal vascular disorder
    Investigated Drugs:
    • Edoxaban
    Austria

  • Study on the Effectiveness and Safety of Obefazimod for Patients with Moderate to Severe Crohn’s Disease After Inadequate Response to Other Treatments

    Recruiting

    2 1
    Investigated Diseases:
    • Crohn’s disease
    Investigated Drugs:
    • Obefazimod
    Belgium Czechia France Germany Hungary Italy +5

  • Study on EXL01 for Preventing Crohn’s Disease Recurrence After Surgery in Patients

    Recruiting

    2 1
    Investigated Diseases:
    • Crohn’s disease
    Investigated Drugs:
    • Exl01
    France

  • Study on Eltrekibart and Mirikizumab for Adults with Moderate to Severe Ulcerative Colitis

    Recruiting

    2 1
    Investigated Diseases:
    • Colitis ulcerative
    Investigated Drugs:
    • Mirikizumab
    • Humanised Igg4 Kappa Monoclonal Antibody Against Cxcl1, Cxcl2, Cxcl3, Cxcl5, Cxcl6, Cxcl7 And Cxcl8
    Belgium Croatia Czechia Denmark France Germany +8

  • Long-term safety study of tulisokibart in adults with Crohn’s disease or ulcerative colitis

    Recruiting

    3 1
    Investigated Drugs:
    • Tulisokibart
    Czechia France Hungary Poland
Previous Page
1 … 14 15 16 17 18 … 93
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!